A new study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that the targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare genetic subtype of early-stage non-small cell lung cancer (NSCLC), potentially offering a new treatment option to help keep the disease from coming back after standard therapy.

The international phase 3 clinical trial, called LIBRETTO-432, found that after two years, 92% of patients with stage II–IIIA RET fusion-positive NSCLC who received selpercatinib after standard treatment were alive without their cancer returning—a measure known as event-free survival—compared with 61% of patients who received a placebo. Overall, the treatment reduced the risk of cancer recurrence or death by 83%.

The results were shared during the Plenary Session on May 31 at the American Society of Clinical Oncology Annual Meeting by Dr. Jonathan Goldman, Health Sciences Clinical Professor in the Department of Medicine at the David Geffen School of Medicine at UCLA. The paper was also published in the New England Journal of Medicine.